Ultralife (NASDAQ:ULBI – Get Free Report) released its earnings results on Friday. The technology company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.18), Zacks reports. Ultralife had a negative net margin of 3.09% and a positive return on equity of 3.10%.
Here are the key takeaways from Ultralife’s conference call:
- Q1 revenue was $47.4 million with an operating loss of $0.2 million and a net loss of $0.5 million (?$0.03/sh), attributed to shipment timing, Middle East delivery delays, plant reorganizations, weather-related interruptions, and pre?revenue staffing and consulting costs.
- Consolidated gross margin dropped to 21.3% (down 380 bps) and gross profit fell 20.7% year?over?year, driven largely by lost production days (Newark substation failure and a 16?day equivalent impact at Raynham during ERP/inventory transition), higher energy costs, and unfavorable sales mix/tariffs.
- The company exited Q1 with a record backlog of $115.1 million (up 21% YoY), representing 61% of trailing?12?month sales and including over $12 million of new?product backlog, providing stronger near?term revenue visibility.
- Management is investing in product development and vertical integration (Electrochem), expects to more than double internal cell usage, shipped the first conformal wearable battery order with > $8 million backlog, and won a $4 million multi?year award—actions intended to stabilize Communications Systems revenue and lift gross margins.
Ultralife Trading Down 15.3%
NASDAQ ULBI traded down $1.08 during trading on Friday, hitting $5.97. The stock had a trading volume of 131,366 shares, compared to its average volume of 44,552. The company has a market capitalization of $99.46 million, a PE ratio of -16.58 and a beta of 0.74. The company has a quick ratio of 1.39, a current ratio of 2.83 and a debt-to-equity ratio of 0.35. The firm has a 50 day moving average price of $6.64 and a 200 day moving average price of $6.30. Ultralife has a twelve month low of $4.78 and a twelve month high of $9.52.
Hedge Funds Weigh In On Ultralife
Ultralife Company Profile
Ultralife Corporation (NASDAQ: ULBI) develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.
See Also
Receive News & Ratings for Ultralife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultralife and related companies with MarketBeat.com's FREE daily email newsletter.
